Concepts (210)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 31 | 2019 | 120 | 10.050 |
Why?
|
| Bronchodilator Agents | 12 | 2019 | 82 | 3.830 |
Why?
|
| Glycopyrrolate | 3 | 2019 | 3 | 2.060 |
Why?
|
| Muscarinic Antagonists | 3 | 2019 | 15 | 1.910 |
Why?
|
| Lung | 7 | 2019 | 235 | 1.800 |
Why?
|
| Smoking | 13 | 2016 | 440 | 1.620 |
Why?
|
| Patient Readmission | 3 | 2017 | 106 | 1.610 |
Why?
|
| Asbestos | 5 | 2015 | 8 | 1.530 |
Why?
|
| Forced Expiratory Volume | 11 | 2019 | 112 | 1.200 |
Why?
|
| Mesothelioma | 3 | 2015 | 38 | 1.120 |
Why?
|
| Asthma | 6 | 2018 | 397 | 1.100 |
Why?
|
| Nebulizers and Vaporizers | 4 | 2018 | 13 | 1.100 |
Why?
|
| Disease Progression | 4 | 2017 | 572 | 1.080 |
Why?
|
| Administration, Inhalation | 10 | 2019 | 92 | 1.010 |
Why?
|
| Ethanolamines | 2 | 2015 | 16 | 0.950 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2018 | 148 | 0.820 |
Why?
|
| Spirometry | 4 | 2019 | 32 | 0.760 |
Why?
|
| Humans | 41 | 2019 | 29295 | 0.750 |
Why?
|
| Adrenergic beta-Agonists | 2 | 2018 | 50 | 0.740 |
Why?
|
| Glucocorticoids | 2 | 2012 | 149 | 0.710 |
Why?
|
| Respiratory System Agents | 1 | 2019 | 1 | 0.700 |
Why?
|
| Middle Aged | 25 | 2019 | 10892 | 0.700 |
Why?
|
| Quinolones | 1 | 2019 | 6 | 0.700 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2015 | 9 | 0.690 |
Why?
|
| Indans | 1 | 2019 | 25 | 0.690 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2015 | 72 | 0.660 |
Why?
|
| Severity of Illness Index | 7 | 2019 | 864 | 0.640 |
Why?
|
| Aged | 21 | 2019 | 9528 | 0.630 |
Why?
|
| Vital Capacity | 5 | 2019 | 44 | 0.630 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 387 | 0.630 |
Why?
|
| Medicare | 2 | 2017 | 188 | 0.610 |
Why?
|
| Male | 28 | 2019 | 17897 | 0.610 |
Why?
|
| Female | 27 | 2019 | 18271 | 0.610 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2010 | 1079 | 0.590 |
Why?
|
| Germ-Line Mutation | 2 | 2015 | 18 | 0.580 |
Why?
|
| Drug Combinations | 4 | 2019 | 86 | 0.560 |
Why?
|
| Treatment Outcome | 8 | 2019 | 3116 | 0.540 |
Why?
|
| Coronary Disease | 2 | 2016 | 200 | 0.530 |
Why?
|
| Benzyl Alcohols | 1 | 2015 | 1 | 0.520 |
Why?
|
| Chlorobenzenes | 1 | 2015 | 2 | 0.520 |
Why?
|
| Quinuclidines | 1 | 2015 | 3 | 0.520 |
Why?
|
| Androstadienes | 1 | 2014 | 17 | 0.500 |
Why?
|
| Patient Selection | 1 | 2016 | 257 | 0.500 |
Why?
|
| Albuterol | 1 | 2014 | 40 | 0.490 |
Why?
|
| Mutation, Missense | 2 | 2015 | 48 | 0.490 |
Why?
|
| Patient Discharge | 1 | 2015 | 170 | 0.490 |
Why?
|
| Length of Stay | 1 | 2015 | 294 | 0.480 |
Why?
|
| Drug Therapy, Combination | 5 | 2018 | 273 | 0.480 |
Why?
|
| Algorithms | 1 | 2016 | 467 | 0.440 |
Why?
|
| Health Status | 5 | 2019 | 370 | 0.430 |
Why?
|
| Adult | 13 | 2019 | 8485 | 0.400 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2019 | 467 | 0.390 |
Why?
|
| Pleural Neoplasms | 2 | 2007 | 11 | 0.380 |
Why?
|
| Drug Administration Schedule | 3 | 2019 | 246 | 0.380 |
Why?
|
| Scavenger Receptors, Class A | 2 | 2010 | 6 | 0.380 |
Why?
|
| Respiratory Function Tests | 4 | 2019 | 111 | 0.380 |
Why?
|
| Codon, Nonsense | 1 | 2010 | 5 | 0.370 |
Why?
|
| Time Factors | 5 | 2019 | 2009 | 0.370 |
Why?
|
| Delayed-Action Preparations | 3 | 2016 | 35 | 0.360 |
Why?
|
| Age Factors | 5 | 2018 | 1115 | 0.350 |
Why?
|
| Promoter Regions, Genetic | 2 | 2007 | 213 | 0.340 |
Why?
|
| Dyspnea | 3 | 2019 | 31 | 0.330 |
Why?
|
| Aged, 80 and over | 6 | 2019 | 3729 | 0.330 |
Why?
|
| Respiratory Therapy | 2 | 2018 | 4 | 0.320 |
Why?
|
| Practice Guidelines as Topic | 3 | 2018 | 375 | 0.310 |
Why?
|
| Recovery of Function | 2 | 2019 | 190 | 0.310 |
Why?
|
| Peritoneal Neoplasms | 2 | 2007 | 241 | 0.300 |
Why?
|
| Interleukin-13 | 1 | 2007 | 33 | 0.300 |
Why?
|
| Comorbidity | 5 | 2016 | 546 | 0.300 |
Why?
|
| Environmental Exposure | 1 | 2007 | 87 | 0.290 |
Why?
|
| Occupational Diseases | 1 | 2006 | 83 | 0.270 |
Why?
|
| Prostate-Specific Antigen | 2 | 2003 | 61 | 0.270 |
Why?
|
| Risk Factors | 9 | 2019 | 3560 | 0.270 |
Why?
|
| United States | 7 | 2018 | 3655 | 0.260 |
Why?
|
| Occupational Exposure | 2 | 2006 | 224 | 0.250 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 327 | 0.250 |
Why?
|
| Logistic Models | 6 | 2016 | 729 | 0.250 |
Why?
|
| Sex Factors | 5 | 2019 | 632 | 0.240 |
Why?
|
| Asbestosis | 1 | 2004 | 1 | 0.240 |
Why?
|
| Prostatic Neoplasms | 3 | 2003 | 442 | 0.230 |
Why?
|
| Prevalence | 7 | 2019 | 908 | 0.230 |
Why?
|
| Inhalation | 2 | 2019 | 8 | 0.210 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 792 | 0.210 |
Why?
|
| Receptors, Androgen | 1 | 2002 | 39 | 0.210 |
Why?
|
| Regression Analysis | 2 | 2017 | 274 | 0.200 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2015 | 838 | 0.200 |
Why?
|
| Polymorphism, Genetic | 1 | 2002 | 196 | 0.200 |
Why?
|
| Smoking Cessation | 3 | 2015 | 135 | 0.190 |
Why?
|
| Cohort Studies | 3 | 2015 | 1697 | 0.180 |
Why?
|
| Sensitivity and Specificity | 3 | 2010 | 533 | 0.180 |
Why?
|
| Patient Education as Topic | 2 | 2018 | 252 | 0.180 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2019 | 10 | 0.170 |
Why?
|
| Prognosis | 4 | 2015 | 1366 | 0.170 |
Why?
|
| Retrospective Studies | 2 | 2017 | 3129 | 0.170 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 26 | 0.170 |
Why?
|
| North Carolina | 3 | 2019 | 1426 | 0.160 |
Why?
|
| Sleep | 1 | 2019 | 87 | 0.160 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 638 | 0.160 |
Why?
|
| Preoperative Care | 1 | 2019 | 110 | 0.160 |
Why?
|
| Patient Care Team | 1 | 2019 | 124 | 0.160 |
Why?
|
| Body Mass Index | 3 | 2016 | 868 | 0.160 |
Why?
|
| Population Surveillance | 2 | 2016 | 119 | 0.160 |
Why?
|
| Inspiratory Capacity | 1 | 2017 | 2 | 0.150 |
Why?
|
| Disease Management | 1 | 2018 | 114 | 0.150 |
Why?
|
| Health Education | 1 | 2018 | 121 | 0.150 |
Why?
|
| Quality of Health Care | 1 | 2018 | 135 | 0.150 |
Why?
|
| Case-Control Studies | 3 | 2010 | 862 | 0.140 |
Why?
|
| Acute Disease | 1 | 2017 | 239 | 0.140 |
Why?
|
| Drug Delivery Systems | 1 | 2017 | 93 | 0.140 |
Why?
|
| Health Expenditures | 1 | 2017 | 61 | 0.140 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 223 | 0.140 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 436 | 0.130 |
Why?
|
| Forecasting | 1 | 2016 | 133 | 0.130 |
Why?
|
| Stereoisomerism | 1 | 2015 | 21 | 0.130 |
Why?
|
| Genotype | 3 | 2007 | 735 | 0.130 |
Why?
|
| Melanoma | 1 | 2015 | 148 | 0.120 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 727 | 0.120 |
Why?
|
| Survival Rate | 1 | 2016 | 796 | 0.120 |
Why?
|
| Double-Blind Method | 1 | 2014 | 504 | 0.110 |
Why?
|
| Probability | 2 | 2004 | 150 | 0.110 |
Why?
|
| Adolescent | 4 | 2016 | 3267 | 0.100 |
Why?
|
| Risk Assessment | 4 | 2015 | 1316 | 0.100 |
Why?
|
| Behavioral Risk Factor Surveillance System | 3 | 2016 | 9 | 0.100 |
Why?
|
| Prospective Studies | 3 | 2019 | 2035 | 0.100 |
Why?
|
| Macrophages | 2 | 2010 | 188 | 0.090 |
Why?
|
| Sex Distribution | 2 | 2016 | 186 | 0.090 |
Why?
|
| Age Distribution | 2 | 2016 | 198 | 0.090 |
Why?
|
| Radiography, Thoracic | 1 | 2010 | 43 | 0.090 |
Why?
|
| Ethics, Professional | 1 | 2009 | 6 | 0.090 |
Why?
|
| Cell Adhesion | 1 | 2010 | 103 | 0.090 |
Why?
|
| Conflict of Interest | 1 | 2009 | 39 | 0.090 |
Why?
|
| Socioeconomic Factors | 3 | 2016 | 394 | 0.090 |
Why?
|
| ADAM Proteins | 1 | 2009 | 13 | 0.090 |
Why?
|
| Neoplasms | 1 | 2015 | 620 | 0.080 |
Why?
|
| Cell Survival | 1 | 2010 | 274 | 0.080 |
Why?
|
| Societies, Medical | 1 | 2009 | 150 | 0.080 |
Why?
|
| Phenotype | 2 | 2009 | 631 | 0.080 |
Why?
|
| Laundering | 1 | 2007 | 4 | 0.080 |
Why?
|
| Clothing | 1 | 2007 | 5 | 0.080 |
Why?
|
| Nuclear Family | 1 | 2007 | 15 | 0.080 |
Why?
|
| Air Pollution, Indoor | 1 | 2007 | 7 | 0.080 |
Why?
|
| Obesity | 1 | 2015 | 1070 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2010 | 801 | 0.080 |
Why?
|
| Linkage Disequilibrium | 2 | 2009 | 192 | 0.080 |
Why?
|
| Homozygote | 1 | 2007 | 57 | 0.080 |
Why?
|
| Heterozygote | 1 | 2007 | 52 | 0.080 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2006 | 20 | 0.070 |
Why?
|
| Family Health | 1 | 2006 | 78 | 0.070 |
Why?
|
| Health Surveys | 2 | 2018 | 191 | 0.070 |
Why?
|
| South Carolina | 2 | 2016 | 29 | 0.070 |
Why?
|
| Educational Status | 1 | 2006 | 165 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 2 | 2003 | 173 | 0.070 |
Why?
|
| Analysis of Variance | 2 | 2003 | 454 | 0.060 |
Why?
|
| Young Adult | 3 | 2016 | 2415 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 89 | 0.060 |
Why?
|
| Allelic Imbalance | 1 | 2003 | 6 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2004 | 169 | 0.060 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2004 | 71 | 0.060 |
Why?
|
| Receptors, Immunologic | 1 | 2002 | 18 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 520 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2004 | 212 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 641 | 0.050 |
Why?
|
| Base Sequence | 1 | 2002 | 242 | 0.050 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 354 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 1371 | 0.050 |
Why?
|
| Linear Models | 2 | 2015 | 427 | 0.050 |
Why?
|
| Child | 1 | 2007 | 2226 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2002 | 251 | 0.050 |
Why?
|
| Mutation | 1 | 2002 | 469 | 0.050 |
Why?
|
| Airway Resistance | 1 | 2019 | 5 | 0.040 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2019 | 47 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 871 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2019 | 268 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2004 | 2117 | 0.040 |
Why?
|
| Equipment Design | 1 | 2017 | 167 | 0.040 |
Why?
|
| Haplotypes | 2 | 2009 | 220 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2015 | 53 | 0.030 |
Why?
|
| Cough | 1 | 2015 | 19 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 92 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 116 | 0.030 |
Why?
|
| Exercise Tolerance | 1 | 2015 | 110 | 0.030 |
Why?
|
| Self-Help Devices | 1 | 2013 | 5 | 0.030 |
Why?
|
| Health Behavior | 1 | 2015 | 216 | 0.030 |
Why?
|
| Arthritis | 1 | 2013 | 37 | 0.030 |
Why?
|
| Hospitalization | 1 | 2016 | 418 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 206 | 0.030 |
Why?
|
| Genetic Markers | 2 | 2003 | 122 | 0.030 |
Why?
|
| Mental Health | 1 | 2013 | 104 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2013 | 240 | 0.030 |
Why?
|
| Incidence | 1 | 2015 | 1123 | 0.030 |
Why?
|
| European Continental Ancestry Group | 2 | 2009 | 1131 | 0.030 |
Why?
|
| Exercise | 1 | 2016 | 595 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 370 | 0.020 |
Why?
|
| Constitution and Bylaws | 1 | 2009 | 3 | 0.020 |
Why?
|
| Organizational Policy | 1 | 2009 | 20 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2009 | 225 | 0.020 |
Why?
|
| Stroke | 1 | 2013 | 550 | 0.020 |
Why?
|
| Hypertension | 1 | 2013 | 914 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2003 | 9 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2003 | 16 | 0.010 |
Why?
|
| Luciferases | 1 | 2003 | 27 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 75 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2003 | 139 | 0.010 |
Why?
|
| Receptors, Scavenger | 1 | 2002 | 7 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2002 | 40 | 0.010 |
Why?
|
| Quality of Life | 1 | 2008 | 824 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2002 | 67 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2002 | 95 | 0.010 |
Why?
|
| Pedigree | 1 | 2002 | 133 | 0.010 |
Why?
|
| African Continental Ancestry Group | 1 | 2002 | 350 | 0.010 |
Why?
|